H.C. Wainwright Reiterates a Buy on Delcath Systems (DCTH), Lowers the PT

​Delcath Systems, Inc. (NASDAQ:DCTH) is one of the Fast-Growing Small Cap Stocks to Buy According to Analysts. On November 5, Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on Delcath Systems, Inc. (NASDAQ:DCTH), but lowered the price target from $31 to $30.

​Earlier on November 4, Delcath Systems, Inc. (NASDAQ:DCTH) released results for its fiscal Q3 2025. The company posted a revenue of $20.6 million, up from $11.2 million last year. Moreover, the EPS came in at $0.02, ahead of the consensus by $0.08. Management attributed revenue growth to HEPZATO KIT and CHEMOSAT revenues. The HEPZATO KIT revenue grew to $19.3 million from $10 million year-over-year, and CHEMOSAT revenue increased from $1.2 million in Q3 2024 to $1.3 million in the latest quarter. Notably, the gross margins also improved from 85% to 87% during the same time.

​However, despite the strong performance, management lowered the full-year revenue guidance and now expects it to be in the range of $83 million to $85 million, down from the previous range of $93 million to $96 million. Management noted that this is due to a slowdown in new patient starts, partially due to summer seasonality.

Delcath Systems, Inc. (NASDAQ:DCTH) is a healthcare company specializing in interventional oncology treatments for liver cancers. Its main products include the HEPZATO KIT and CHEMOSAT Hepatic Delivery System.

While we acknowledge the potential of DCTH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.